Health
Bavarian Says It Can Meet Mpox Shot Demand, Shares Jump
- Pricing is going to be an issue, CEO Paul Chaplin says
- Africa outbreak has been declared a continent-wide emergency
Vials of Bavarian Nordic’s Jynneos vaccine.
Photographer: Kobi Wolf/BloombergThis article is for subscribers only.
Bavarian Nordic A/S, one of the few companies with an approved mpox vaccine, says it will be able to meet the immunization needs of African nations in the throes of an mpox outbreak.
Shares in the Danish company surged as much as 17% in early Thursday trading in Copenhagen, extending a 12% rise the day before, after it said it can provide 10 million doses of its vaccine to African countries by the end of 2025.